Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Trevigen Receives Grant for Cell Line Panel

October 27, 2010 8:08 am | News | Comments

Trevigen, Inc., a leader in providing specialized products for the study of DNA damage and cancer cell behavior, announced that it is the primary recipient of a NIGMS, two-year Phase 2 Grant for $2,526,726.

TOPICS:

Pharmaxis Announces Phase 3 Data

October 27, 2010 8:03 am | News | Comments

Pharmaceutical company Pharmaxis announced significant results of pooled data from its two large scale six month Phase 3 trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis.

TOPICS:

Nymox BPH Drug in Phase 3 Trials

October 27, 2010 7:59 am | News | Comments

Nymox Pharmaceutical Corporation provided an update on the company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The Safety Monitoring Committee meeting was favorable and indicated no significant safety concerns.

TOPICS:
Advertisement

FDA Tells BMS to Fix Puerto Rico Plant

October 27, 2010 7:46 am | by Linda A. Johnson | News | Comments

U.S. regulators have told drugmaker Bristol-Myers Squibb Co. they won't approve an important new drug until the company fixes multiple deficiencies at its Puerto Rico manufacturing plant, the company's CEO has disclosed.

TOPICS:

GSK Settles $750M Adulterated Drug Suit

October 27, 2010 7:41 am | by Denise Lavoie | News | Comments

British pharmaceutical company GlaxoSmithKline PLC will pay $750 million to settle allegations that it knowingly manufactured and sold adulterated drugs, including the popular antidepressant Paxil, federal prosecutors in Massachusetts said.

TOPICS:

Database Launched to Personal Cancer Treatment

October 27, 2010 7:27 am | News | Comments

An overall goal of the Georgetown Database of Cancer is to accelerate the personalization of medical treatment for patients. G-DOC means that physicians and researchers need only access a single website to open a universe of information on cancer.

TOPICS:

Cetuximab May Work for Some Colorectal Cancer Patients

October 27, 2010 7:23 am | News | Comments

Research indicates that patients with a variant of KRAS-mutated metastatic colorectal tumors who don't respond to chemotherapy and were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations.

TOPICS:

Reaction to Sleep Deprivation May Be Genetic

October 27, 2010 7:15 am | News | Comments

A study looked at people who have a gene variant that is closely associated with narcolepsy, a sleep disorder that causes excessive daytime sleepiness. However, having the gene variant, called DQB1 *0602, does not mean that a person will develop narcolepsy.

TOPICS:
Advertisement

Gene Variants Lead to Worse Outcome with Clopidogrel

October 27, 2010 7:08 am | News | Comments

New analysis indicates that use of clopidogrel in patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events.

TOPICS:

Study Identifies Key Molecules in Multiple Myeloma

October 27, 2010 7:04 am | News | Comments

New research links three molecules to a critical tumor suppressor gene that is often turned off in multiple myeloma, a presently incurable cancer of the blood. The findings might offer a new strategy for treating this disease and other blood cancers.

TOPICS:

Haptoglobin Biomarker for Virus-induced Diabetes

October 27, 2010 7:00 am | News | Comments

In addition to genetic susceptibility, it is generally accepted that environmental factors play important roles in triggering Type 1 diabetes, with virus infection having perhaps the strongest association.

TOPICS:

New Research Says lncRNA Affects Immune Response

October 27, 2010 6:56 am | News | Comments

Scientists have demonstrated for the first time that long non-protein-coding RNA (lncRNA) are involved in the host response to viral infection. These findings could greatly change the way scientists look at the body's response to viral infection.

TOPICS:

Widefield Fluorescence System

October 26, 2010 8:17 am | Product Releases | Comments

Leica Microsystems has extended its automated high-content screening solution to cover applications on widefield fluorescence systems. The Leica HCS A package enables fast and efficient multi-position experiments.

TOPICS:

Bisulfite Conversion Kit

October 26, 2010 8:11 am | Product Releases | Comments

EMD Millipore, the life science division of Merck KGaA of Germany, announced the introduction of a rapid kit for bisulfite conversion, which is a critical first step in mapping the differences in genomic DNA methylation patterns.

TOPICS:

Celtic And Resolvyx Sign Deal for RX-10045

October 26, 2010 8:02 am | News | Comments

Celtic Therapeutics Holdings L.P. and Resolvyx Pharmaceuticals, Inc. announced that they have entered into an option agreement relating to Resolvyx’s RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading